Pemvidutide
Also known as: ALT-801, ALT801
Classification
Peptide
Regulatory Status
Overview
Pemvidutide (ALT-801) is an investigational unacylated peptide dual agonist of the GLP-1 and glucagon receptors, studied for MASLD/MASH and obesity.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
ClassB source cannot establish canonical regulatory or safety fields. The statements below are retained as uncertainty, not as a label-backed verdict. | Regulatory status: not-established | Contraindication: No approved US label contraindications; investigational dual agonist should not be treated as an authorized consumer product | Warning: Trial programs report gastrointestinal adverse events typical of incretin-based agonists; full labeled risk profile is not established pending approval | Adverse effect: gastrointestinal events reported in clinical trials | Serious adverse effect: full serious-risk profile not established in an approved US label
Pathways
Interactions & cautions
Drug interactions
other GLP-1, dual, or triple incretin agonists — Additive GI effects, glycemic effects, or monitoring burden may occur. (review)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.